AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03932487 — intervention group
Intervention type: OTHER
Intervention: urinary iodine and urine BPA
Description: urinary iodine and urine BPA
Study NCT02888769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week. Prior to study commencement, a bank of 280 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
Study NCT03986749 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Doppler ultrasonography after bursa augmentation
Description: Dynamic ultrasound examination with Grading of blood vessels using the modified Ohberg Score in the longitudinal scan in dynamic ultrasound of the rotator cuff tendon - primary to surgery and 3 weeks later.
Study NCT02109133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deep neuromuscular blockade
Description: deep neuromuscular blockade using rocuronium and reverse with sugammadex
Study NCT02109133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: moderate neuromuscular blockade
Description: moderate neuromuscular blockade using atracurium and reverse with neostigmine
Study NCT02109133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Study NCT02109133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Study NCT02109133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium
Study NCT02109133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Study NCT00373685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: open-label
Study NCT00373685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Any commercially available NSAID with the indication for osteoarthritis
Description: dosing as per USPI label related to the chosen commercially marketed NSAID
Study NCT02125578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017 (PEGylated Interferon Beta-1a)
Description: Each participant will receive BIIB017 every other week or every 4 weeks.
Study NCT02125578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB017 (PEGylated Interferon Beta-1a)
Description: Each participant will receive BIIB017 every other week or every 4 weeks.
Study NCT02125578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each participant will receive placebo every other week or every 4 weeks.
Study NCT01154153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: 1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.
Study NCT01154153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Description: 1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.
Study NCT01154153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)
Description: Treatment assignment was randomized with stratification by sex and age group (>=2 to \<6, >=6 to \<12 years old).~* For children who were >=2 to \<6 years old, 1 spray/nostril (110 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.~* For children who were >=6 yrs to \<12 years old, either 1 spray/nostril (110 µg TAA-AQ) or 2 sprays/nostril (220 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.
Study NCT01154153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Treatment assignment was randomized with stratification by sex and age group (>=2 to \<6, >=6 to \<12 years old).~* For children who were >=2 to \<6 years old, 1 spray/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.~* For children who were >= 6 yrs to \<12 years old, either 1 spray/nostril or 2 sprays/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.
Study NCT01154153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Claritin® Syrup
Description: Children's Claritin® Syrup \[5 mg of loratadine per 5 mL\] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.
Study NCT01154153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Claritin® Syrup
Description: Children's Claritin® Syrup \[5 mg of loratadine per 5 mL\] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.
Study NCT00819650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licartin (generic name,[131I]metuximab injection)
Description: Licartin, radioiodination of Metuximab with Na\[131I\],with radiochemical purity above 95% and specific activity between 173.25-288.75 MBq/ml.All patients in the treatment group received Licartin 3 times at an interval of 28 days beginning from the 4th week after liver resection
Study NCT01566292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Botulinum Toxin type A, 200-300 UI dilued in 6 ml of saline solution
Study NCT01724359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: The recommended Paliperidone extended-release (ER) dose will be 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily. Adjustment of the dosage will be done at the investigator's discretion.
Study NCT04694040 — intervention group
Intervention type: DEVICE
Intervention: Modjaw® device
Description: Analysis of mandibular kinematics with Modjaw® device
Study NCT03676023 — intervention group
Intervention type: DRUG
Intervention: Tranexamic Acid
Description: Inhalation of Transexamic acid in age adjusted dosing
Study NCT03626610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise prehabilitation during chemotherapy before surgery
Description: Monitored exercise training in patients with a new diagnosis of oesophageal adenocarcinoma
Study NCT02448628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150
Study NCT01690065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib+AD induction
Description: • Post-remission consolidation chemotherapy~* 4 courses of high-dose cytarabine will be given as post-remission therapy. Cytarabine 3 g/m2 will be administered in a 3-hour iv infusion every 12 hours on days 1, 3, and 5 (a total of six doses per course).~* Nilotinib 400mg bid PO will be administered continuously during consolidation chemotherapy and for 2 years after the consolidation therapy or until allogeneic hematopoietic stem cell transplantation
Study NCT02140489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amosartan
Study NCT02140489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Study NCT02365051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care of Persons with Dementia in their Environments
Description: In-home visits by occupational therapist and advanced practice nurse.
Study NCT02140489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amosartan and rosuvastatin
Study NCT00683150 — intervention group
Intervention type: OTHER
Intervention: Endothelial Function Test
Description: Endothelial function tests performed within 20 days before surgery, when surgery begins (at the time of incision), every hour during surgery and then 1, 2, 3, and 5 days after surgery.
Study NCT03505632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recruitment with low PEEP
Description: Volume controlled ventilation with TV 6-8 ml/PBW . RR adjusted to keep the EtCO2 35-40 mmHg. I/E ratio1:2 and FiO2 0.40.Patients will receive PEEP of 5cmH2O. RM will be done by increasing the PEEP in stepwise manner. First PEEP increase to 10 cmH2O (3 breaths),then to 15 cm H2O (3 breaths) and finally PEEP raise to 20 cmH2O (10 breaths).Then PEEP decrease by 5 cmH2O increments every (3 breaths) until back to PEEP 5 cmH2O. RM will take 2 minutes. RM will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40 cmH2O. Monitoring of the following parameters :Dynamic lung compliance ,Horowitz index ,dead space and driving pressure .
Study NCT03505632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High PEEP without RM
Description: Volume controlled ventilation will carried out with tidal volume 6-8 ml/kg for predicted body weight. The PBW calculated according to the formula : 50 + 0.91 × {height (cm)-152.4} for men and 45.5 + 0.91 × {height (cm) - 152.4} for women. The respiratory rate adjusted to keep the EtCO2= 35-40 mmHg. The inspiratory to expiratory ratio (I:E ratio) 1:2 and FiO2 0.40.Patients will receive high PEEP of 15cmH2O from the start and continue all through the procedure . Monitoring of dynamic lung compliance,Horowitz index,dead space and driving pressure will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40cmH2O.
Study NCT03223298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 37.5 units injected into each masseter muscle and 12.5 units into each temporalis muscle
Study NCT03223298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: 1cc syringe
Study NCT04494425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan by intravenous infusion
Study NCT00424606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 75 mg/m2 intravenously (IV) every 3 weeks for 4 consecutive cycles
Study NCT00424606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin at the dose of 90 mg/m2 IV every 3 weeks for 4 consecutive cycles
Study NCT00424606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
Study NCT00424606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
Study NCT02758093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed of Processing Training
Description: These are specific computerized exercises that are designed to increase the rate in which people can process visual information.
Study NCT02758093 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Internet Navigational
Description: This is a sham condition in which participants will receive the same amount of social and computer contact as those randomized to receive the 10 hours of speed of processing training. In this condition, participants will learn how to do various activities on the internet.
Study NCT03871400 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior cervical discectomy and fusion
Description: primary, 2-level, contiguous
Study NCT04494425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Investigator's choice standard of care single agent chemotherapy; capecitabine tablets will be given orally.
Study NCT04494425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Investigator's choice standard of care single agent chemotherapy; paclitaxel by intravenous infusion.
Study NCT04494425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Investigator's choice standard of care single agent chemotherapy; nab-paclitaxel by intravenous infusion
Study NCT02579642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Low dose ketamine 0.2 mg/kg (or 0.5 mg/kg depending on results of interim analysis) administered with usual induction drugs for ECT
Study NCT04586790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Oral Tablet
Description: midodrine group will receive midodrine 10 mg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral midodrine .
Study NCT04586790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minirin oral tablet
Description: Minirin group will receive minirin 60 µg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral minirin .
Study NCT04586790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nor-Adrenaline
Description: control group will receive IV nor-adrenaline and is gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .
Study NCT02579642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline administered with usual induction drugs for ECT
Study NCT03575923 — intervention group
Intervention type: BEHAVIORAL
Intervention: Urban street greening
Description: The interventions are located on four publicly accessible sites; the total size of the floor area of green space in each of the intervention sites is small, ranging from 0.09 to 0.35 acres. Components of the interventions include tree and flower planting (expected to bloom by March 2018) and artificial tree decorations such as strings of small electric lights and tree socks (the interventions are hereafter collectively referred to as urban street greening). The total cost for all components across all four intervention sites is approximately £6,000, although this excludes artist fees connected to the project. All components of the interventions were implemented within a one week period in November 2017 by two arborists, two local artists, staff members at Southway Housing Trust, and local community members from Old Moat and a local school.
Study NCT03089086 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed 4CMenB vaccine
Description: Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month to \<3 months apart in adolescents.
Study NCT00920426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 30mg
Description: GSK1265744 30 mg
Study NCT00920426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match GSK1265744
Study NCT00920426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 5mg
Description: GSK1265744 5mg
Study NCT05556408 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Succinylcholine
Description: 1.5mg/kg was given intravenously
Study NCT02532777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT03152747 — intervention group
Intervention type: DEVICE
Intervention: ultrasound, b-scan
Description: Some selected centres will participate in a substudy. In the substudy population, if the vitreous cortex is not visible on OCT both in the study eye and the fellow eye, or if the OCT is of poor quality and most likely will not allow definite diagnosis, a B-scan ophthalmic ultrasound will be performed by an experienced examiner. The presence or absence of a PVD in the ultrasound measurement will be recorded in the case report form (CRF). If ultrasonography was not performed, allocation to the groups is based on the staging of the reading centre. Otherwise ultrasonography will be used for final diagnosis and group allocation if the reading centre classifies the OCT as not decisive.
Study NCT02532777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide(CTX)
Study NCT02532777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil(MMF)
Study NCT02532777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide(LEF)
Study NCT02532777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor(ACEI)
Study NCT02532777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study NCT04484922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: continuous infusion of dexmedetomidine during the surgery
Study NCT04484922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: continuous infusion of normal saline during the surgery
Study NCT00002571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: 5u/m2 IV Q21days x 6 cycles
Study NCT04952324 — intervention group
Intervention type: OTHER
Intervention: Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and HS CRP
Description: Periferal Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and high sensitive CRP
Study NCT00002571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5ug/kg SC, Days 9-20, Q 21 days x 6 cycles
Study NCT00002571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 490 mg/m2 IV Q 21 days x 6 cycles
Study NCT01808690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT01808690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00002571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 225 mg/m2 IV Q 21 days x 6 cycles
Study NCT02516618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab
Study NCT00002571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 19 mg/m2 IV Q 21 days x 6 cycles
Study NCT00002571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 90 mg/m2 IV Q 21 days x 6 cycles
Study NCT02516618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02644460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Study NCT00002571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 25 mg/m2 po 24 hours after methotrexate Q 6 hours x 4 doses for 6 cycles.
Study NCT00002571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 90 mg/m2 IV, Q 21 days x 6 cycles.
Study NCT00002571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60 mg/m2 po QD x 14days for 6 cycles
Study NCT00002571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole
Description: 1 double throughout strength treatment tablet po on Monday, Wednesday, and Friday x 6, 21 day cycles
Study NCT00002571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.4 mg/m2 IV Q 21 Days x 6 cycles
Study NCT00002571 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: All patients achieving a CR or PR following systemic therapy and IT Ara-C, will receive 2,400 cGy in two hundred cGy fractions to the whole brain. Fields should adequately encompass all meningeal surfaces.
Study NCT00002571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal cytarabine
Description: If initial bone marrow positive:~Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first two cycles of therapy. Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle.~If initial CSF cytology positive:~Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first cycle of therapy. If CSF negative after above, Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle. If CSF positive after initial five doses of Ara-C, IT MTX 12 mg per dose x 5 doses should be given spaced evenly during the second cycle of therapy.~If initial bone marrow and CSF negative:~Ara-C 30 mg/m2 IT per dose x 5 doses to be given spaced evenly within 1 month of completion of systemic therapy.
Study NCT04108169 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial appendage occlusion surgery
Description: CABG according to indications in the current guidelines on myocardial revascularization including surgical closure of left atrial appendage
Study NCT01589003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Glycaemic index growing up milk
Description: Low Glycaemic index growing up milk
Study NCT01589003 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High GI growing up milk
Description: High glycaemic index growing up milk
Study NCT02245191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: 5mg after Spinal Anesthesia
Study NCT02245191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: 100mcg after Spinal Anesthesia
Study NCT02245191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metaraminol
Description: 200mcg Metaraminol after Spinal Anesthesia
Study NCT01109459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pediatric blood pressure screening
Description: Website presenting case-based education with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.